



#11  
Rec'd Seq. List.  
Amdt. B  
7/10/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Confirmation No. 8019  
Takeru FUJII et al. : Docket No. 2001-0019A  
Serial No. 09/757,655 : Group Art Unit 1648  
Filed January 11, 2001 : Examiner S. Brown

A PEPTIDE HAVING AN AFFINITY  
FOR gp120

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

RESPONSE

Assistant Commissioner for Patents,  
Washington, D.C. 20231

*One B' before  
placed  
els.*

Sir:

Responsive to the Notice dated March 27, 2002, there is submitted herewith, in a separate Preliminary Amendment, a paper copy of a Sequence Listing for the above-identified application which has been prepared in accordance with the sequence rules under 37 CFR 1.821-1.825. The Sequence Listing contains the identical sequences appearing in the original application papers. Thus, no new matter has been added.


There is also submitted herewith a copy of the Sequence Listing in computer readable form as required by 37 CFR 1.821(e). The content of the paper and computer readable copies are the same.

A copy of the Notice is also attached as required.

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Takeru FUJII et al.

By:   
Lee Cheng  
Registration No. 40,949  
Attorney for Applicants

LC/gtg  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
June 27, 2002



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/757,655	01/11/2001	Takeru Fujii	2001_0019A	8019

513 7590 03/27/2002

WENDEROTH, LIND & PONACK, L.L.P.  
2033 K STREET N. W.  
SUITE 800  
WASHINGTON, DC 20006-1021



EXAMINER

BROWN, STACY S

ART UNIT PAPER NUMBER

1648

DATE MAILED: 03/27/2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED  
APR - 1 2002  
WENDEROTH, LIND & PONACK



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS

20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.



EXAMINER	
ART UNIT	PAPER NUMBER
9	

**Please find below a communication from the EXAMINER in charge of this application**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN ONE EXTENDABLE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio  
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS  
Submission User Manual - ePAVE)

2. Mailed to:  
**U.S. Patent and Trademark Office**  
**Box Sequence, P.O. Box 2327**  
**Arlington, VA 22202**

3. Mailed by Federal Express, United Parcel Service or other delivery service to:

**U. S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, Box Sequence  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, Virginia 22202**

4. Hand Carried directly to the Customer Window at:


**2011 South Clark Place  
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,  
Arlington, Virginia 22202**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Stacy S. Brown whose telephone number is (703) 308-2361. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner James Housel whose telephone number is (703) 308-4027. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

*Stacy S. Brown*

Stacy S. Brown  
March 26, 2002



HANKYEL T. PARK, PH.D  
PRIMARY EXAMINER



Application No.: 09/757,655

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200


To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

2. Brown

Re-run

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



## RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/757,655

Source: 1600

Date Processed by STIC: 2/21/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER  
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND  
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name,  
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,  
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,  
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

# Raw Sequence Listing Error Summary

## ERROR DETECTED

## SUGGESTED CORRECTION

SERIAL NUMBER: 09/757,655

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics  
Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to 3; this will prevent "wrapping."
- 2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino  
Numbering The numbering under each 5<sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0  
"bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s). Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 Skipped Sequences  
(OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:  
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
This sequence is intentionally skipped  
  
Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 Skipped Sequences  
(NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.  
<210> sequence id number  
<400> sequence id number  
000
- 9 Use of n's or Xaa's  
(NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.  
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  
In <220> to <223> section, please explain location of n or Xaa; and which residue n or Xaa represents.
- 10 Invalid <213>  
Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 Use of <220> Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.  
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 PatentIn 2.0  
"bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 Misuse of n n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.





16

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/757,655

DATE: 02/21/2002  
TIME: 11:38:41

Input Set : A:\FUJII SEQUENCE LISTING.txt  
Output Set: N:\CRF3\02212002\I757655.raw

Does Not Comply  
Corrected Diskette Needed

pg 1-5

RECEIVED

JUL 08 2002

TECH CENTER 1600/2900

3 <110> APPLICANT: FUJII, Takeru  
4 YOKOYAMA, Hideakira  
5 HAMAMOTO, Hidetoshi  
7 <120> TITLE OF INVENTION: A PEPTIDE HAVING AN AFFINITY FOR gp120  
9 <130> FILE REFERENCE: 2001-0019A/LC/01732  
11 <140> CURRENT APPLICATION NUMBER: 09/757,655  
12 <141> CURRENT FILING DATE: 2001-01-11  
14 <150> PRIOR APPLICATION NUMBER: JP No. 2000-6182  
15 <151> PRIOR FILING DATE: 2000-01-11  
17 <160> NUMBER OF SEQ ID NOS: 19  
19 <170> SOFTWARE: PatentIn Ver. 2.0  
21 <210> SEQ ID NO: 1  
22 <211> LENGTH: 5  
23 <212> TYPE: PRT  
24 <213> ORGANISM: Artificial Sequence  
26 <220> FEATURE:  
27 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
29 <220> FEATURE:  
W--> 30 <221> NAME/KEY: Residue  
31 <222> LOCATION: (1)  
32 <223> OTHER INFORMATION: Xaa = Asp, Lys, Val, Glu, Gly, Asn or Tyr  
34 <220> FEATURE:  
W--> 35 <221> NAME/KEY: Residue  
36 <222> LOCATION: (2)  
37 <223> OTHER INFORMATION: Xaa = Val, Asp, Trp, Lys, Phe, Ile, Leu or Tyr  
39 <220> FEATURE:  
W--> 40 <221> NAME/KEY: Residue  
41 <222> LOCATION: (3)  
42 <223> OTHER INFORMATION: Xaa = Lys, Val, Asp, Arg, Ala or Trp  
44 <220> FEATURE:  
W--> 45 <221> NAME/KEY: Residue  
46 <222> LOCATION: (4)  
47 <223> OTHER INFORMATION: Xaa = Ala, Trp or Gly  
49 <220> FEATURE:  
W--> 50 <221> NAME/KEY: Residue  
51 <222> LOCATION: (5)  
52 <223> OTHER INFORMATION: Xaa = Gly, Ala, Val, Leu, Ile, Ser, Thr, Met, Asn, Gln, His, Lys, Arg,  
53 Phe, Trp, Pro or Tyr  
55 <400> SEQUENCE: 1  
56 Xaa Xaa Xaa Xaa Xaa  
57 1 5  
59 <210> SEQ ID NO: 2  
60 <211> LENGTH: 5

insufficient explanation  
give source  
of genetic  
material  
(see item  
on Enn  
summary  
sheet)

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/757,655

DATE: 02/21/2002

TIME: 11:38:41

Input Set : A:\FUJII SEQUENCE LISTING.txt

Output Set: N:\CRF3\02212002\I757655.raw

61 <212> TYPE: PRT  
62 <213> ORGANISM: Artificial Sequence  
64 <220> FEATURE:  
65 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
67 <220> FEATURE:  
W--> 68 <221> NAME/KEY: Residue  
69 <222> LOCATION: (1)  
70 <223> OTHER INFORMATION: Xaa = Asp, Lys, Val, Glu, Gly, Asn or Tyr, or polypeptide residue that an  
71 arbitrary amino acid stood in line in the N-terminal side from this amino ac  
73 <220> FEATURE:  
W--> 74 <221> NAME/KEY: Residue  
75 <222> LOCATION: (2)  
76 <223> OTHER INFORMATION: Xaa = Val, Asp, Trp, Lys, Phe, Ile, Leu or Tyr  
78 <220> FEATURE:  
W--> 79 <221> NAME/KEY: Residue  
80 <222> LOCATION: (3)  
81 <223> OTHER INFORMATION: Xaa = Lys, Val, Asp, Arg, Ala or Trp  
83 <220> FEATURE:  
W--> 84 <221> NAME/KEY: Residue  
85 <222> LOCATION: (4)  
86 <223> OTHER INFORMATION: Xaa = Ala, Trp or Gly  
88 <220> FEATURE:  
W--> 89 <221> NAME/KEY: Residue  
90 <222> LOCATION: (5)  
91 <223> OTHER INFORMATION: Xaa = Gly, Ala, Val, Leu, Ile, Ser, Thr, Met, Asn, Gln, H:  
Lys, Arg,  
92 Phe, Trp, Pro or Tyr  
94 <400> SEQUENCE: 2  
W--> 95 Xaa Xaa Xaa Xaa Xaa  
96 1 5  
98 <210> SEQ ID NO: 3  
99 <211> LENGTH: 5  
100 <212> TYPE: PRT  
101 <213> ORGANISM: Artificial Sequence  
103 <220> FEATURE:  
104 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
106 <220> FEATURE:  
W--> 107 <221> NAME/KEY: Residue  
108 <222> LOCATION: (1)  
109 <223> OTHER INFORMATION: Xaa = Asp, Lys, Val, Glu, Gly, Asn or Tyr  
111 <220> FEATURE:  
W--> 112 <221> NAME/KEY: Residue  
113 <222> LOCATION: (2)  
114 <223> OTHER INFORMATION: Xaa = Val, Asp, Trp, Lys, Phe, Ile, Leu or Tyr  
116 <220> FEATURE:  
W--> 117 <221> NAME/KEY: Residue  
118 <222> LOCATION: (3)  
119 <223> OTHER INFORMATION: Xaa = Lys, Val, Asp, Arg, Ala or Trp  
121 <220> FEATURE:  
W--> 122 <221> NAME/KEY: Residue

PAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/757,655

DATE: 02/21/2002  
TIME: 11:38:41

Input Set : A:\FUJII SEQUENCE LISTING.txt  
Output Set: N:\CRF3\02212002\I757655.raw

123 <222> LOCATION: (4)  
124 <223> OTHER INFORMATION: Xaa = Ala, Trp or Gly  
126 <220> FEATURE:  
W--> 127 <221> NAME/KEY: Residue  
128 <222> LOCATION: (5)  
129 <223> OTHER INFORMATION: Xaa = Gly, Ala, Val, Leu, Ile, Thr, Met, Asn, Gln, His, Lys  
Arg,  
130 Phe, Trp, Pro or Tyr, or polypeptide residue that an arbitrary amino acid  
131 stood in line in the C-terminal side of this amino acid, H  
133 <400> SEQUENCE 3  
W--> 134 Xaa Xaa Xaa Xaa Xaa  
135 1 5  
138 <210> SEQ ID NO: 4  
139 <211> LENGTH: 5  
140 <212> TYPE: PRT  
141 <213> ORGANISM: Artificial Sequence  
143 <220> FEATURE:  
144 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
146 <220> FEATURE:  
W--> 147 <221> NAME/KEY: Residue  
148 <222> LOCATION: (1)  
149 <223> OTHER INFORMATION: Xaa = Tyr, Arg, Phe, Gly, Trp, His or Asp  
151 <220> FEATURE:  
W--> 152 <221> NAME/KEY: Residue  
153 <222> LOCATION: (2)  
154 <223> OTHER INFORMATION: Xaa = Arg, Tyr, Trp, Ala, Val, Gln, His or Lys  
156 <220> FEATURE:  
W--> 157 <221> NAME/KEY: Residue  
158 <222> LOCATION: (3)  
159 <223> OTHER INFORMATION: Xaa = Lys, Tyr, Arg, Glu, Met or Trp  
161 <220> FEATURE:  
W--> 162 <221> NAME/KEY: Residue  
163 <222> LOCATION: (4)  
164 <223> OTHER INFORMATION: Xaa = Gly, Ala, Val, Leu, Ile, Ser, Thr, Met, Asn, Gln, His  
Lys, Arg,  
165 Phe or Trp  
167 <220> FEATURE:  
W--> 168 <221> NAME/KEY: Residue  
169 <222> LOCATION: (5)  
170 <223> OTHER INFORMATION: Xaa = Gly, Ala, Val, Leu, Ile, Ser, Thr, Met, Asn, Gln, His  
Lys, Arg,  
171 Phe, Tyr or Trp  
173 <400> SEQUENCE 4  
W--> 174 Xaa Xaa Xaa Xaa Xaa  
175 1 5  
177 <210> SEQ ID NO: 5  
178 <211> LENGTH: 5  
179 <212> TYPE: PRT  
180 <213> ORGANISM: Artificial Sequence  
182 <220> FEATURE:  
183 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
185 <220> FEATURE:

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/757,655

DATE: 02/21/2002

TIME: 11:38:41

Input Set : A:\FUJII SEQUENCE LISTING.txt

Output Set: N:\CRF3\02212002\I757655.raw

W--> 186 <221> NAME/KEY: Residue  
 187 <222> LOCATION: (1)  
 188 <223> OTHER INFORMATION: Xaa = Tyr, Arg, Phe, Gly, Trp, His or Asp, or polypeptide residue that an  
 189 arbitrary amino acid stood in the N-terminal side from this amino acid  
 191 <220> FEATURE:

W--> 192 <221> NAME/KEY: Residue  
 193 <222> LOCATION: (2)  
 194 <223> OTHER INFORMATION: Xaa = Arg, Tyr, Trp, Ala, Val, Gln, His or Lys  
 196 <220> FEATURE:

W--> 197 <221> NAME/KEY: Residue  
 198 <222> LOCATION: (3)  
 199 <223> OTHER INFORMATION: Xaa = Lys, Tyr, Arg, Glu, Met or Trp  
 201 <220> FEATURE:

W--> 202 <221> NAME/KEY: Residue  
 203 <222> LOCATION: (4)  
 204 <223> OTHER INFORMATION: Xaa = Gly, Ala, Val, Leu, Ile, Ser, Thr, Met, Asn, Gln, His, Lys, Arg,  
 205 Phe or Trp  
 207 <220> FEATURE:

W--> 208 <221> NAME/KEY: Residue  
 209 <222> LOCATION: (5)  
 210 <223> OTHER INFORMATION: Xaa = Gly, Ala, Val, Leu, Ile, Ser, Thr, Met, Asn, Gln, His, Lys, Arg,  
 211 Phe, Tyr or Trp  
 213 <400> SEQUENCE: 5  
 214 Xaa Xaa Xaa Xaa Xaa  
 215 1 5  
 217 <210> SEQ ID NO: 6  
 218 <211> LENGTH: 5  
 219 <212> TYPE: PRT  
 220 <213> ORGANISM: Artificial Sequence  
 222 <220> FEATURE:  
 223 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
 225 <220> FEATURE:

W--> 226 <221> NAME/KEY: Residue  
 227 <222> LOCATION: (1)  
 228 <223> OTHER INFORMATION: Xaa = Tyr, Arg, Phe, Gly, Trp, His or Asp  
 230 <220> FEATURE:

W--> 231 <221> NAME/KEY: Residue  
 232 <222> LOCATION: (2)  
 233 <223> OTHER INFORMATION: Xaa = Arg, Tyr, Trp, Ala, Val, Gln, His or Lys  
 235 <220> FEATURE:

W--> 236 <221> NAME/KEY: Residue  
 237 <222> LOCATION: (3)  
 238 <223> OTHER INFORMATION: Xaa = Lys, Tyr, Arg, Glu, Met or Trp  
 240 <220> FEATURE:

W--> 241 <221> NAME/KEY: Residue  
 242 <222> LOCATION: (4)  
 243 <223> OTHER INFORMATION: Xaa = Gly, Ala, Val, Leu, Ile, Ser, Thr, Met, Asn, Gln, His, Lys, Arg,  
 244 Phe or Trp  
 246 <220> FEATURE:

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/757,655

DATE: 02/21/2002  
TIME: 11:38:41

Input Set : A:\FUJII SEQUENCE LISTING.txt  
Output Set: N:\CRF3\02212002\I757655.raw

W--> 247 <221> NAME/KEY: Residue  
248 <222> LOCATION: (5)  
249 <223> OTHER INFORMATION: Xaa = Gly, Ala, Val, Leu, Ile, Ser, Thr, Met, Asn, Gln, His  
Lys, Arg,  
250 Phe, Tyr or Trp, or polypeptide residue that an arbitrary amino acid stood in  
line  
251 in the C-terminal side of this amino acid  
253 <400> SEQUENCE: 6/  
W--> 254 Xaa Xaa Xaa Xaa Xaa  
255 1 5  
257 <210> SEQ ID NO: 7  
258 <211> LENGTH: 7  
259 <212> TYPE: PRT  
260 <213> ORGANISM: Artificial Sequence  
262 <220> FEATURE:  
263 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
265 <400> SEQUENCE: 7  
266 Gly Gly Asp Val Lys Ala Gly  
267 1 5  
269 <210> SEQ ID NO: 8  
270 <211> LENGTH: 6  
271 <212> TYPE: PRT  
272 <213> ORGANISM: Artificial Sequence  
274 <220> FEATURE:  
275 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
277 <400> SEQUENCE: 8  
278 Gly Asp Val Lys Ala Gly  
279 1 5  
281 <210> SEQ ID NO: 9  
282 <211> LENGTH: 6  
283 <212> TYPE: PRT  
284 <213> ORGANISM: Artificial Sequence  
286 <220> FEATURE:  
287 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
289 <400> SEQUENCE: 9  
290 Gly Tyr Tyr Lys Ala Ala  
291 1 5  
293 <210> SEQ ID NO: 10  
294 <211> LENGTH: 6  
295 <212> TYPE: PRT  
296 <213> ORGANISM: Artificial Sequence  
298 <220> FEATURE:  
299 <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide  
301 <400> SEQUENCE: 10  
302 Gly Tyr Ala Tyr Arg Lys  
303 1 5  
305 <210> SEQ ID NO: 11  
306 <211> LENGTH: 6  
307 <212> TYPE: PRT  
308 <213> ORGANISM: Artificial Sequence  
310 <220> FEATURE:

*Please correct  
this error in  
subsequent sequence*

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/757,655

DATE: 02/21/2002

TIME: 11:38:42

Input Set : A:\FUJII SEQUENCE LISTING.txt

Output Set: N:\CRF3\02212002\I757655.raw

L:30 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1  
L:35 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1  
L:40 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1  
L:45 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1  
L:50 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1  
L:56 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:68 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2  
L:74 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2  
L:79 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2  
L:84 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2  
L:89 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2  
L:95 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2  
L:107 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3  
L:112 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3  
L:117 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3  
L:122 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3  
L:127 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3  
L:134 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:147 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4  
L:152 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4  
L:157 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4  
L:162 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4  
L:168 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4  
L:174 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4  
L:186 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5  
L:192 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5  
L:197 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5  
L:202 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5  
L:208 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5  
L:214 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:226 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6  
L:231 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6  
L:236 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6  
L:241 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6  
L:247 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6  
L:254 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6